13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
Oric Pharmaceuticals Inc. (ORIC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 6,572,700 | $36,675,666 | +49% | 0.12% |
| 2. | Alkeon Capital Management Panayotis Takis Sparaggis | 4,004,096 | $22,342,856 | +3% | 0.05% |
| 3. | EcoR1 Capital Oleg Nodelman | 3,418,068 | $19,072,819 | 1.13% | |
| 4. | Vivo Capital Albert Cha And Frank Kung | 2,080,450 | $11,608,911 | +63% | 1.54% |
| 5. | SilverArc Capital Devesh Gandhi | 2,060,240 | $11,496,139 | +75% | 2.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.82 | 76,072 | Officer, Director | 802,652 | 2022-05-13 | Filing | |
| $2.75 | 69,354 | Officer, Director | 726,580 | 2022-05-12 | Filing | |
| $2.90 | 304,574 | Officer, Director | 657,226 | 2022-05-11 | Filing | |
| $5.36 | 60,000 | Officer | 60,000 | 2022-03-31 | Filing | |
| $4.54 | 50,000 | Officer, Director | 352,652 | 2022-03-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.28 | 8,851 | 106,764 | 2024-12-16 | Filing | ||
| $8.28 | 8,850 | 46,765 | 2024-12-16 | Filing | ||
| $8.28 | 24,660 | 778,648 | 2024-12-16 | Filing | ||
| $16.21 | 40,000 | 728,544 | 2024-03-06 | Filing | ||
| $12.30 | 26,042 | 768,544 | 2024-02-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,435,087 | $30,327,787 | 0% | |
| 2. | 5,376,344 | $30,000,000 | 5.99% | |
| 3. | 5,285,714 | $29,494,284 | 6.85% | |
| 4. | 3,540,777 | $19,757,536 | 44.67% | |
| 5. | 3,215,887 | $17,944,648 | 0% |
News See All
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
10 Most Shorted Stocks That Are Loved by Analysts
Short selling is one of the more controversial ways of making money on the stock market.
Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets
In this article, we discuss the 5 stocks receiving price-target hike from Wall Street analysts.
10 Best Biotech Stocks Under $10
In this article, we will take a look at the 10 best Biotech stocks under $10.
Hedge Fund and Insider Trading News: Ray Dalio, Jana Partners, Odey Asset Management, Citadel LLC, Coatue Management, Westbeck Capital Management, ORIC Pharmaceuticals Inc (ORIC), and More
London hedge fund Odey Asset Management reckons IGO’s joint venture with Andrew Forrest’s Wyloo Metals short-changes minority shareholders in IGO’s $1.07 billion bid for Western Areas.
10 Best Biotech and AI Stocks To Buy According To Quant Billionaire Jim Simons
Euclidean Capital is the family office of billionaire hedge fund manager James "Jim" Simons.
10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we reviewed Jim Simons' investment strategy, historical performance, and family office portfolio.
5 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we discuss the 5 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Is ORIC A Good Stock To Buy Now?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Billionaire Hedge Funds
